Clinical Report: Effects of Tirzepatide on MASLD in Obese Patients
Overview
This study evaluates the effects of tirzepatide on metabolic dysfunction-associated steatotic liver disease (MASLD) in obese patients. Significant reductions in body weight, BMI, waist circumference, fasting glucose, HbA1c, hs-CRP, and FLI were observed after three months of treatment.
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease globally, closely linked to obesity and metabolic syndrome. Effective management strategies are essential due to the disease's association with increased cardiovascular risk and type 2 diabetes, as noted in recent literature. Tirzepatide, a dual GIP and GLP-1 receptor agonist, has shown promise in addressing these metabolic challenges.
Data Highlights
Parameter
Baseline
3 Months
P-value
Body Weight
Not Reported
Significant Reduction
<0.001
BMI
Not Reported
Significant Reduction
<0.001
Waist Circumference
Not Reported
Significant Reduction
<0.001
Fasting Glucose
Not Reported
Improvement
0.001
HbA1c
Not Reported
Improvement
<0.001
hs-CRP
Not Reported
Significant Reduction
<0.001
FLI
Not Reported
Significant Decrease
<0.001
Key Findings
Tirzepatide treatment resulted in significant reductions in body weight, BMI, and waist circumference.
Improvements in fasting glucose, HbA1c, insulin levels, and HOMA-IR were observed.
hs-CRP levels showed a significant reduction.
Liver enzymes (AST, ALT, GGT) and lipid parameters significantly decreased, except for triglycerides.
FLI decreased significantly from baseline to three months.
Δhs-CRP was identified as the only independent predictor of ΔFLI.
Clinical Implications
Monitoring inflammatory markers may provide insights into treatment outcomes.
Conclusion
Tirzepatide demonstrates significant effects on MASLD and associated metabolic dysfunctions in obese patients. Further studies are warranted to confirm these findings.
